Cubist Systematic Strategies, LLC Tricida, Inc. Transaction History

Cubist Systematic Strategies, LLC

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.14 - $12.49 $21,134 - $1.89 Million	-150,958 Reduced 86.05%	24,468 $3,000
Q3 2022 Nov 14, 2022	BUY	$8.51 - $13.6 $868,513 - $1.39 Million	102,058 Added 139.1%	175,426 $1.84 Million
Q2 2022 Aug 15, 2022	BUY	$7.31 - $11.85 $327,334 - $530,631	44,779 Added 156.63%	73,368 $710,000
Q1 2022 May 16, 2022	BUY	$7.35 - $10.63 $161,126 - $233,030	21,922 Added 328.81%	28,589 $235,000
Q3 2021 Nov 15, 2021	SELL	$3.56 - $4.64 $13,528 - $17,632	-3,800 Reduced 36.3%	6,667 $31,000
Q2 2021 Aug 16, 2021	SELL	$3.95 - $5.41 $69,891 - $95,724	-17,694 Reduced 62.83%	10,467 $45,000
Q1 2021 May 17, 2021	SELL	$4.52 - $7.8 $181,428 - $313,084	-40,139 Reduced 58.77%	28,161 $149,000
Q4 2020 Feb 16, 2021	BUY	$4.37 - $9.46 $15,526 - $33,611	3,553 Added 5.49%	68,300 $482,000
Q3 2020 Nov 16, 2020	BUY	$8.56 - $26.93 $223,672 - $703,680	26,130 Added 67.66%	64,747 $587,000
Q2 2020 Aug 14, 2020	BUY	$21.21 - $31.55 $459,302 - $683,215	21,655 Added 127.67%	38,617 $1.06 Million
Q1 2020 May 15, 2020	SELL	$18.43 - $38.04 $321,198 - $662,961	-17,428 Reduced 50.68%	16,962 $373,000
Q4 2019 Feb 14, 2020	BUY	$29.6 - $43.71 $1.02 Million - $1.5 Million	34,388 Added 1719400.0%	34,390 $1.3 Million
Q3 2019 Nov 14, 2019	BUY	$29.87 - $42.22 $59 - $84	2 New	2 $0
Q2 2019 Aug 14, 2019	SELL	$31.16 - $39.46 $132,710 - $168,060	-4,259 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$19.96 - $38.62 $29,740 - $57,543	1,490 Added 53.81%	4,259 $164,000
Q4 2018 Feb 14, 2019	BUY	$23.57 - $32.33 $65,265 - $89,521	2,769 New	2,769 $65,000

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.